Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Nisha Joseph

Nisha Joseph

MD
Emory University School of Medicine
Phase II dose optimization study of inobrodib with pomalidomide and dexamethasone in R/R myeloma 2:34
Phase II dose optimization study of inobrodib with pomalidomide and dexamethasone in R/R myeloma
Nisha Joseph • 7 Dec 2025
Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more 12:44
Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more
Ajai Chari et al. • 23 Oct 2025
Stem cell mobilization with Dara-RVD induction in newly diagnosed myeloma: a real-world experience 1:14
Stem cell mobilization with Dara-RVD induction in newly diagnosed myeloma: a real-world experience
Nisha Joseph • 8 Dec 2024
A Phase I/II trial of iberdomide for the treatment of intermediate- or high-risk smoldering myeloma 2:28
A Phase I/II trial of iberdomide for the treatment of intermediate- or high-risk smoldering myeloma
Nisha Joseph • 8 Dec 2024
AutoSCT for elderly patients with multiple myeloma in their last quarter of life 1:06
AutoSCT for elderly patients with multiple myeloma in their last quarter of life
Nisha Joseph • 10 Dec 2023
Real-world comparison of D-RVd and RVd induction in patients with newly diagnosed multiple myeloma 1:33
Real-world comparison of D-RVd and RVd induction in patients with newly diagnosed multiple myeloma
Nisha Joseph • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals